Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » MDx Company DxNA Buying PCR-based Assay Development Firm PathoGene

MDx Company DxNA Buying PCR-based Assay Development Firm PathoGene

Jul 17, 2013
|
staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics shop DxNA has signed a letter of intent to acquire PCR-based assay development company PathoGene, the companies said this week.

Terms of the deal were not revealed, but the companies said the acquisition is anticipated to be completed during the next six months, contingent on the completion of due diligence and other conditions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Robots for the Lab

Researchers have developed a robotic lab assistant, the Verge reports.

Ruling Awaited

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

To Find Where It Came From

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

Science Presents Atlas of Aberrant Cells in Lung Condition, More

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
16
Featured Webinar

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Sponsored by
NanoString

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In PCR

  1. Qiagen Reports Preliminary Q2 Revenue Growth of 18 to 19 Percent

  2. FDA Grants EUAs for Enzo Life Sciences, Access Bio, Gene By Gene Coronavirus Tests

  3. FDA Letter Warns About False-Positive Results From Becton Dickinson SARS-CoV-2 Test

  4. BioMérieux Reports 62 Percent BioFire FilmArray Sales Growth in Preliminary Q2 Release

  5. FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.